Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival
Recent Boosts Also Include EIR For Nagpur Plant As Well As US Lurasidone Launch
Executive Summary
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.
You may also be interested in...
Latuda Enters ‘Twilight’ Phase Pending Generic Competition
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
Lupin Expands US Inhalation Business With Two Sunovion Brands
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India